In parallel, recent phase 2 and 3 clinical trials have demonstrated the therapeutic potential of glucagon-like peptide-1 (GLP-1) receptor agonists (e.g., liraglutide, semaglutide), GIP/GLP-1 dual receptor agonists (e.g., tirzepatide), glucagon/GLP-1 dual receptor agonists (e.g., pemvidutide, survodutide), and glucagon/GIP/GLP-1 triple receptor agonists (e.g., efocipegtrutide) for the treatment of MASH [14–18]. This evidence concerns the gene GIP and metabolic dysfunction-associated steatohepatitis.